Effect of sodium ozagrel on the activity of rat CYP2D6

被引:5
|
作者
Wu, Hong
Yu, Weijiang
Huang, Lijun
Wang, Jing
Tang, Xiaobo
Yang, Wei
Liu, Yan
Yu, Huiyan
Zhu, Daling
机构
[1] Harbin Med Univ, Coll Pharm, Harbin 150081, Heilongjiang, Peoples R China
[2] Biopharmaceut Key Lab Heilongjiang Prov, Harbin 150081, Peoples R China
[3] Mudanjiang Med Coll, Mudanjiang 157011, Peoples R China
关键词
ozagrel-1; CYP2D6; microsorne; HPLC; dextromethorphan;
D O I
10.1016/j.ejphar.2007.06.055
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the study was to investigate the influence of sodium ozagrel on CYP2D6 (cytochromeP450 2D6) activity. The studies were performed with rat urine and liver microsomes and chemical inhibitors. The metabolism of dextromethorphan (dextrophan/dextromethorphan, dextrophan is a metabolite of dextromethorphan) and phenacetin (paracetamol/phenacetin, paracetamol is a metabolites of phenacetin) was used as probe to measure CYP2D6 and CYP1A2 (cytochromeP450 1A2) activity, respectively, determined by high-performance liquid chromatography (HPLC). The results showed that the metabolism of dextrophan/dextromethorphan in the sodium ozagrel-treated group (37 mg/kg) was higher than that of the control (P < 0.05/6) in both in vivo and in vitro studies (r=0.9811). The rate of dextromethorphan metabolism was inhibited by sodium ozagrel and cimetidine in rat liver microsomes prepared from sodium ozagrel-treated rats and control rats group (sodium ozagrel IC50=26.5 mu M, cimetidine IC50=86.3 mu M in sodium ozagrel-treated group; sodium ozagrel IC50=13.9 mu M, cimetidine IC50=24.8 mu M in control group). The inhibitory effect of sodium ozagrel on CYP2D6 activity was noncompetitive with dextromethorphan with a K-i of 324.94 mu M. Kinetic parameters of the reactions were established by using Lineweaver-Burk with K-m=0.67 mM and V-max = 2.13 pm/min/mg protein for the sodium ozagrel-treated group and K-m=0.29 mM, and V-max =0.91 pm/min/mg protein for the control group, respectively. The expression of CYP2D6 protein in the treated group was higher than that of the control group, as determined by Western blotting. The activity and expression of CYP1A2 did not show obvious differences in the control group and sodium ozagrel treated group. In conclusion, sodium ozagrel metabolism in rats is mediated primarily through CYP2D6, and sodium ozagrel can induce CYP2D6 activity. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:55 / 59
页数:5
相关论文
共 50 条
  • [21] Assessment of CYP2D6 activity in depressed patients
    Szewczuk-Bogusawska, M
    Orzechowska-Juzwenko, K
    Milejski, P
    Beszlej, JA
    Grzesiak, M
    Kiejna, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S219 - S219
  • [22] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [23] CYP2D6 activity in methadone maintenance patients
    Shiran, MR
    Rostami-Hodjegan, A
    Lennard, MS
    Iqbal, MZ
    Lagundoye, O
    Pratt, P
    Seiveright, N
    Tucker, GT
    JOURNAL OF PSYCHOPHARMACOLOGY, 2002, 16 (03) : A54 - A54
  • [24] The use of Yohimbine for phenotyping of CYP2D6 activity
    Vay, M.
    Rose, P.
    Meyer, M.
    Mikus, G.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S24 - S24
  • [25] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
  • [26] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [27] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [28] No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers
    Avenoso, A
    Facciolà, G
    Scordo, MG
    Spina, E
    THERAPEUTIC DRUG MONITORING, 1999, 21 (05) : 577 - 579
  • [29] The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity
    Welzen, Marieke E. B.
    Dezentje, Vincent O.
    van Schaik, Ron H. N.
    Colbers, Angela P. H.
    Guchelaar, Henk-Jan
    van Erp, Nielka P.
    den Hartigh, Jan
    Burger, David M.
    van Laarhoven, Hanneke W. M.
    THERAPEUTIC DRUG MONITORING, 2015, 37 (04) : 501 - 507
  • [30] The effect of tobacco on lung cancer risk depends on CYP2D6 activity
    Bouchardy, C
    Benhamou, S
    Dayer, P
    CANCER RESEARCH, 1996, 56 (02) : 251 - 253